secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2023-01-11T23:59:59+00:00
Accession:  0000950170-23-000640
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo expects to meet 2022 total revenue guidance of $460-480M; cash ~$1.3B
----------------------------------------------------------------------------

- Expects 55-60 new Cell Programs added in 2022, nearly doubling 2021 additions.
- Foundry revenue expected below $150-170M guidance; Biosecurity revenue exceeds $310M.
- Ended 2022 with approx. $1.3B cash; strong liquidity despite challenging macro.
- Opened Bioworks7 (6,600 sq ft BSL-2 lab) for mammalian cell engineering; launched Ginkgo Enzyme Services.
- Full audited Q4 and FY 2022 results due March 2023; 2023 outlook to be provided then.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000095017023000640/0000950170-23-000640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000095017023000640/dna-20230111.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer